AYUR.CN Ayurcann CNQ down 66.67% to C$0.005 on CCAA filing: sale process ahead
AYUR.CN stock dropped 66.67% to C$0.005 on 31 Jan 2026 during market hours after Ayurcann Holdings Corp. filed for creditor protection under the CCAA and announced a sale process. The move triggered a CIRO trading halt and a sharp surge in volume to 2,544,383 shares, far above the 50-day average of 84,668. We review the near-term catalysts, the company’s financial snapshot and what the filing means for shareholders on the Canadian (CNQ) market.
Price plunge and trading activity for AYUR.CN stock
The immediate market reaction was severe: AYUR.CN opened at C$0.01 and closed at C$0.005, a one-day loss of 66.67% on heavy volume of 2,544,383. Trading volume was roughly 30.05x the average, signaling forced selling and headline-driven exits.
The CSE listing and CIRO halt amplified volatility. CIRO halted trading on 30 Jan and later resumed the same day, adding short-term uncertainty to liquidity and potential delisting risk.
Why the CCAA filing moved AYUR.CN stock
Ayurcann announced creditor protection under the Companies’ Creditors Arrangement Act to pursue restructuring and a sale process. That filing puts a formal stay on creditor claims and allows management to seek debtor-in-possession financing to keep operations running.
This is a clear negative catalyst for equity holders because the company explicitly flagged possible suspension or delisting by the CSE and intends to run a sale process that may prioritize creditor recoveries over existing equity values.
Financial snapshot and valuation for AYUR.CN stock
Key metrics show stress and low market value: market cap is CAD 973,519.00, shares outstanding 194,703,863, EPS -0.03, and a negative PE of -0.17. Price averages are weak at a 50-day average of 0.024 and 200-day average of 0.029.
On the positives side, price-to-sales is low at 0.03, free cash flow yield is 0.65, and enterprise value sits at CAD 550,667.00, which could make the business attractive for acquirers if assets and contracts are intact.
Technicals, volume and sector context for AYUR.CN stock
Technically, the stock shows oversold short-term readings with RSI around 48.66 and ADX at 38.79, indicating a strong trend. The one-day drop pushed the price to the multi-month low of C$0.005, equal to the year low.
Sector context matters: Ayurcann operates in Healthcare and Drug Manufacturers – Specialty & Generic, a sector showing mixed performance. Sector averages have higher P/E and stronger margins, which highlights AYUR.CN’s relative weakness versus peers.
Meyka AI grade and forecast for AYUR.CN stock
Meyka AI rates AYUR.CN with a score out of 100: 69.81 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Meyka AI’s forecast model projects a short-term monthly target of C$0.03 and a one-year level of C$0.01728. Versus the current price C$0.005, that implies upside of 500.00% short-term and 245.70% at one year. Forecasts are model-based projections and not guarantees.
Risks and what to watch next for AYUR.CN stock
Primary risks are creditor outcomes, potential delisting, and dilution if DIP financing converts to equity. The CCAA process often prioritizes creditors and buyers, leaving limited recovery for shareholders.
Watch the Monitor’s updates, any DIP financing approval, and sale process timelines. Key dates: earnings announcement expected 2026-03-04, which could affect negotiations and bidder interest.
Final Thoughts
AYUR.CN stock’s sharp decline to C$0.005 on 31 Jan 2026 reflects an equity market reaction to a high-impact corporate action: creditor protection under the CCAA and an announced sale process. Volume spiked to 2,544,383 shares and the market cap sits at CAD 973,519.00, underlining how much value the market has removed. Investors should treat the equity as speculative until the monitor publishes sale process details. Meyka AI’s models show a possible short-term recovery to C$0.03 (+500.00%) and a one-year projection of C$0.01728 (+245.70%), but those projections assume either a successful turnaround or a buyer that values assets above current trading prices. Given the CCAA proceedings, downside scenarios include suspension, delisting, or significant equity dilution. We recommend monitoring the Monitor’s website and court filings, and using position size limits if speculating. For ongoing coverage and data, see the CIRO trading notices and the company press release linked below and the Meyka AI AYUR.CN dashboard for real-time updates.
FAQs
Why did AYUR.CN stock fall so sharply on 31 Jan 2026?
AYUR.CN stock plunged after Ayurcann filed for creditor protection under the CCAA and announced a sale process. The CCAA filing, plus a CIRO trading halt and heavy selling, drove the one-day decline to C$0.005.
What is Meyka AI’s view and grade for AYUR.CN stock?
Meyka AI rates AYUR.CN with a score out of 100: 69.81, Grade B, Suggestion HOLD. The grade factors in benchmark and sector comparisons, growth and key metrics. This is informational, not investment advice.
What are realistic near-term price targets for AYUR.CN stock?
Meyka AI’s forecast model projects a monthly target of C$0.03 and a one-year level of C$0.01728. These imply large percentage upside from C$0.005 but are model-based projections and not guarantees.
What should shareholders watch next for AYUR.CN stock?
Shareholders should monitor the Monitor’s website for sale process details, any court approvals of DIP financing, CSE listing status, and the company’s upcoming earnings announcement on 2026-03-04.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
